Revealing Breakthrough Mitochondrial Science for IPF
Time: 4:00 pm
day: Day Two
- Analyze how CohBar is harnessing the power of mitochondria peptides to target a wide range of chronic and age-related diseases associated with mitochondrial dysfunction, including IPF
- Review CohBar’s clinical candidate, CB5138-3, in development for IPF which has demonstrated positive effects including reduction of fibrosis, inflammation, and collagen deposition.
- Discuss other potential antifibrotic indications for CB5138-3